Navigation Links
Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
Date:1/17/2013

Davis, California and Seoul, South Korea (PRWEB) January 17, 2013

Eckert & Ziegler Vitalea Science (EZVS) and BioCore Co. Ltd., leading bioanalytical contract research organizations (CRO), are pleased to announce the initiation of an agreement to co-market complementary services in support of clinical drug development for the pharmaceutical industry. BioCore, the first bioanalytical CRO in Korea, has an established reputation for quality service and a customer base that extends throughout Asia. This relationship expands BioCore’s portfolio, adding EZVS’s Accelerator Mass Spectrometry (AMS) based services to their suite of advanced offerings, and facilitates EZVS’s entry into the rapidly growing Asian pharmaceutical market.

AMS is an ultrasensitive radiocarbon detection platform that complements other tools available to the pharmaceutical scientist. “Atom counting” sensitivity enable new avenues of clinical drug development in ways that were not previously possible. For example, microdosing allows the behavior of any drug to be studied with almost no risk of side effects. BioCore President and CEO Hyung Sik Choie comments, “Eckert & Ziegler Vitalea Science (EZVS) and BioCore Co. Ltd., leading bioanalytical contract research organizations (CRO), are pleased to announce the initiation of an agreement to co-market complementary services in support of clinical drug development for the pharmaceutical industry. BioCore, the first bioanalytical CRO in Korea, has an established reputation for quality service and a customer base that extends throughout Asia. This relationship expands BioCore’s portfolio, adding EZVS’s Accelerator Mass Spectrometry (AMS) based services to their suite of advanced offerings, and facilitates EZVS’s entry into the rapidly growing Asian pharmaceutical market.

AMS is an ultrasensitive radiocarbon detection platform that complements other tools available to the pharmaceutical scientist. “Atom counting” sensitivity enable new avenues of clinical drug development in ways that were not previously possible. For example, microdosing allows the behavior of any drug to be studied with almost no risk of side effects. BioCore President and CEO Hyung Sik Choie comments, “This alliance brings capabilities through the BioCore interface with immediate benefit to the Korean pharmaceutical community by reducing the timeline to bring new drugs to market.” These studies, while approved under FDA and ICH guidances, are not currently being performed in Korea due to the lack of bio accelerator expertise.

EZVS’s team of experts includes the founders of applied AMS methods for biological determinations and innovators of next generation BioMICADAS AMS technology. Dr. Stephen Dueker, EZVS CSO, stated, “We are very pleased to be represented by BioCore. Alignment with the foremost CRO in Korea provides EZVS presence in Asia and strengthens our credibility as we introduce the benefits of applied AMS into new territory.” The agreement combines the technical expertise of both companies to deliver solutions designed to streamline the drug development process and accelerate commercialization to pharmaceutical sponsors.

About BioCore
BioCore is South Korea's largest provider of bioanalytical liquid chromatography-tandem mass spectrometry (LC/MS/MS) services. BioCore was South Korea's first GLP-complaint centralized bioanalytical CRO (2005) and first to be certified by the Korea Food and Drug Administration as a Bioequivalence Testing Institution (2008).

About EZVS
Eckert & Ziegler Vitalea Science is an integrated provider of isotopes and isotope measurement and calibration services with the Davis, California facility dedicated to GLP level bioanalysis. Founded in 2003, by researchers from the University of California, EZVS is the first U.S.-based bioanalytical contract research organization dedicated to providing services for exploring the pharmacokinetics and metabolism of drug candidates directly in humans and non-clinical species using AMS, both prior to and as part of phase I clinical trials. In our Davis, CA facility, we utilize the BioMICADAS, the only AMS instrument purpose-built to address the specific needs of the pharmaceutical industry.

For further information, please contact:

Eckert & Ziegler Vitalea Science
2121 Second St. Suite B101
Davis, CA 95618
T: +1.530.341.0200
F: +1.530.341.0299
http://www.vitaleascience.com

Media contact:
Ann Hoffman
T: +1.801.706.2237
E: ahoffman(at)vitaleascience(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10328760.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sustainable Valley Technology Group Provides Technology Innovation Grant To Help Researchers & Start-Ups With Funding, Business Support, Equipment & Facilities
2. Precision Coating to Showcase Next Generation Coating Deposition Technology at MD&M West Show in Anaheim, California
3. Mobility and Big Data Analytics Provider NuWare Announces the Appointment of Rohit Shyam as Chief Strategy & Marketing Officer
4. iLuv Introducing NFC & Qi-Certified Technology to Bluetooth Speaker Lineup at 2013 CES
5. Market for Biologic Imaging Reagents and Medical Imaging & Diagnosing Analyzed in New Research Reports at ReportsnReports.com
6. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
7. DuPont Tate & Lyle Bio Products Announces Innovation Award Program
8. LA Dental Bone Graft Substitute & Other Biomaterials Market Reviewed in New iData Research Report Available at MarketPublishers.com
9. WCCT Global (WCCT) & Verified Clinical Trials (VCT) Announce Medication Adherence Documentation Capabilities Have Been Added to the VCT Clinical Trials Database Registry
10. Brownfield Science & Technology Inc. Honored for Professional Services Excellence
11. Asia-Pacific Active Pharmaceutical Ingredients (APIs) Market Analysis & Forecasts to 2017 in New Research Report @ RnRMarketResearch.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
Breaking Biology News(10 mins):